ReviewFrontiers in medicine2026
Transcutaneous auricular vagus nerve stimulation after cesarean delivery: current evidence and trial design priorities.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-cesarean recovery includes uterine contraction pain, incisional pain, nausea, sleep loss, breastfeeding concerns, and early mood symptoms. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation method that has recently been tested after cesarean delivery. This review summarizes the current evidence and asks how future studies should be designed. A structured search of PubMed, Embase, Web of Science Core Collection, Cochrane CENTRAL, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Chinese Clinical Trial Registry, China National Knowledge Infrastructure, and Wanfang was used to identify direct obstetric studies, selected perioperative studies from non-obstetric surgery, and mechanistic papers relevant to post-cesarean recovery. In total, 18 studies were retained. Only one adequately powered randomized trial directly tested taVNS after cesarean delivery. In that trial, 156 women undergoing elective cesarean delivery received active or sham taVNS once daily on the day of surgery and postoperative days 1 and 2. Active stimulation was associated with a lower incidence of moderate-to-severe uterine contraction pain on postoperative day 3. Early incisional pain, sleep, anxiety, and EPDS scores also favored active stimulation, but one-month anxiety and EPDS scores did not differ. Evidence for postoperative nausea and vomiting, ileus, lactation, and postpartum depression prevention remains indirect or trial-stage only. Current evidence supports further multicenter obstetric trials of taVNS, mainly for uterine contraction pain. It does not support routine clinical use. Future studies should use clear sham procedures, formal blinding assessment, objective biomarkers, lactation outcomes, and follow-up to at least 6 weeks postpartum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.